Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Before or after? study tests best time for insulin in type 1 diabetes

NCT ID NCT02546401

Disease control Sponsor: University Hospital, Brest Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at whether taking a fast-acting insulin (Insulin Aspart) before or after meals makes a difference in blood sugar control for people with type 1 diabetes who use an insulin pump. Twenty-two adults participated, and their blood sugar was tracked continuously for 14 days. The goal was to see if injecting after meals, which many patients already do, is a safe and effective option.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Insulin Aspart
What this could lead to
If successful, this could clarify whether taking insulin after meals is as effective as before meals, giving patients more flexibility in managing their diabetes.
What could go wrong
This is a small, completed trial with only 22 participants, so results may not apply to everyone. It does not test a new treatment, only timing of an existing one.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

22 people

The number who actually took part.

Start date

Sep 2015

Finished

Mar 2016

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 80 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Major patients with type 1 diabetes treated with insulin pump. Exclusion Criteria: * Unbalanced diabetes, * Ongoing pregnancy known, * Gastrointestinal neuropathy known, * Chronic medical illness and psychiatric

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Diabetes type 1 are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

type 1 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Diabetes type 1

Contacts and locations

Locations

  • CHRU Brest

    Brest, 29200, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.